TNBC: Metronomic Capecitabine Maintenance Improves Outcomes

Metronomic capecitabine maintenance after standard treatment has been shown to be a successful therapy for patients with triple-negative breast cancer (TNBC) in a recent study. Results of this study will be reported on later this week in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. Relapse and unfavorable outcomes are still issues among patients with TNBC. According to lead study author XI Wang, MD of the Department of Breast Oncology at Sun Yat-Sen Universit...
Continue reading

Toripalimab for Advanced Gastric Cancer

​In a phase 1b/2 clinical trial, researchers report promising results for an immunotherapy drug called toripalimab in patients with advanced gastric cancer. Toripalimab is a monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) from binding to the PD-1 ligand, preventing the activation of PD-1 and its downstream signaling pathways. This allows for certain aspects of the immune system to be restored, such as the activation of T cells and T-cell-mediated immune responses against...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.